Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of chronic neurological conditions, today announced it received approval from the U.S. Food and Drug Administration (FDA) to proceed with the U.S. clinical development of AV411 (ibudilast)...Avigen is currently conducting a Phase IIa study of AV411 in Australia for the treatment of diabetic neuropathic pain and was recently approved by the FDA to initiate a large Phase I clinical trial in the United States...Tuesday, August 14, 2007
Avigen, Neuropathic Pain : Clinical Development for AV411
Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of chronic neurological conditions, today announced it received approval from the U.S. Food and Drug Administration (FDA) to proceed with the U.S. clinical development of AV411 (ibudilast)...Avigen is currently conducting a Phase IIa study of AV411 in Australia for the treatment of diabetic neuropathic pain and was recently approved by the FDA to initiate a large Phase I clinical trial in the United States...
